ObsEva SA (OBSV): Price and Financial Metrics
GET POWR RATINGS... FREE!
OBSV Stock Price Chart Interactive Chart >
OBSV Price/Volume Stats
|Current price||$1.67||52-week high||$3.58|
|Prev. close||$1.72||52-week low||$1.08|
|Day high||$1.77||Avg. volume||711,709|
|50-day MA||$1.47||Dividend yield||N/A|
|200-day MA||$2.06||Market Cap||130.21M|
ObsEva SA (OBSV) Company Bio
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. The company was founded in 2012 and is based in Switzerland.
Most Popular Stories View All
OBSV Latest News Stream
|Loading, please wait...|
OBSV Latest Social Stream
View Full OBSV Social Stream
Latest OBSV News From Around the Web
Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.
With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!
If you want to know who really controls ObsEva SA ( NASDAQ:OBSV ), then you'll have to look at the makeup of its share...
ObsEva (OBSV) signed a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in markets outside of the U.S., Canada and Asia.OBSV…
- Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an oral GnRH antagonist in development for the management of moderate to severe symptoms of uterine fibroids and endometriosis-associated pain - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland, Feb. 10, 2022 (G
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV – Research Report), Inozyme Pharma (INZY – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments. ObsEva SA (OBSV) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $15.00. The company's shares closed last Friday at $1.43, close to its 52-week low of $1.35. According to TipRanks.
OBSV Price Returns